What is the impact factor of The Lancet Oncology?

The Lancet Oncology has an impact factor of 35.9 (2024). This places it among the top-tier journals in its field with The Lancet Oncology publishes cancer research that changes practice globally.

How long does Lancet Oncology take to review?

The Lancet Oncology typically takes ~14 days (very fast). The full review process involves 5 main stages: presubmission inquiry (optional), full submission, and peer review.

Is The Lancet Oncology peer reviewed?

Yes, The Lancet Oncology is fully peer reviewed. All submissions undergo rigorous peer review by Expert oncologists and methodologists. Focus on clinical significance and implementation potential..

All Journal Guides

Journal Guide

The Lancet Oncology Impact Factor 35.9: Publishing Guide

Q: What is the acceptance rate of The Lancet Oncology?

The Lancet Oncology has an acceptance rate of ~8%. A common reason for rejection is submitting phase 2 trials as practice-changing. Promising early results belong in specialty journals. Lancet Oncology wants definitive Phase 3 data that establishes new standards of care.

Q: What does Lancet Oncology look for in submissions?

Practice-changing clinical impact: Will oncologists change how they treat patients after reading your paper? The bar isn't statistical significance; it's clinical significance that matters globally.

Q: What should I know before submitting to Lancet Oncology?

Speed is genuinely valued and expected. 14-day editorial decisions aren't marketing; they're real. If your research is time-sensitive (new drug approval, emerging resistance), this is your venue.

Practice-changing oncology with lightning-fast decisions: where global cancer research meets clinical impact

35.9

Impact Factor (2024)

~8%

Acceptance Rate

~14 days (very fast)

Time to First Decision

What Lancet Oncology Publishes

The Lancet Oncology publishes cancer research that changes practice globally. Part of the Lancet family, it combines the rigorous editorial standards of The Lancet with deep oncology expertise. They want studies that oncologists worldwide will discuss at tumor boards the week they're published.

Phase 3 clinical trials that establish new standards of cancer care
Global cancer epidemiology and health equity research
Practice-changing diagnostic and therapeutic innovations
Cancer policy research with international implications
Real-world evidence studies that complement trial data

Editor Insight

“Lancet Oncology serves the global oncology community. We want research that will change practice in Mumbai as much as in Manhattan. If your findings only apply to well-resourced settings, consider whether the research addresses truly global cancer challenges.”

What Lancet Oncology Editors Look For

Practice-changing clinical impact

Will oncologists change how they treat patients after reading your paper? The bar isn't statistical significance; it's clinical significance that matters globally.

Global cancer perspective

Like all Lancet journals, global relevance matters here more than most journals. How does your research apply across healthcare systems, especially in resource-limited settings?

Exceptionally fast editorial process

Lancet Oncology prides itself on rapid decisions. Time-sensitive cancer research gets priority. Be prepared for quick turnaround and rapid revision cycles.

Multidisciplinary oncology relevance

Your work should matter to medical oncologists, surgical oncologists, radiation oncologists, and related specialists. Narrow subspecialty appeal limits impact.

Patient-centered outcomes

Overall survival, quality of life, patient-reported outcomes: these matter as much as response rates. Cancer care isn't just about tumor shrinkage.

Health equity considerations

Cancer disparities, access to care, and outcomes across populations are increasingly important. Address equity explicitly when relevant.

Why Papers Get Rejected

These patterns appear repeatedly in manuscripts that don't make it past Lancet Oncology's editorial review:

Submitting Phase 2 trials as practice-changing

Promising early results belong in specialty journals. Lancet Oncology wants definitive Phase 3 data that establishes new standards of care.

Single-country studies without global framing

If your study is from one healthcare system, articulate relevance to other contexts. What's generalizable? What's system-specific?

Ignoring health equity dimensions

Cancer disparities are a global crisis. If your research has implications for equity or access, failing to address this is a missed opportunity.

Focusing only on tumor response

Quality of life, functional status, and patient experience matter. A treatment that shrinks tumors but destroys quality of life needs careful evaluation.

Slow response to editorial requests

Lancet Oncology moves fast. If you can't commit to rapid revisions and quick responses, consider whether this is the right venue.

Missing global cancer burden context

How does your research address major cancer challenges worldwide? Connection to global cancer priorities strengthens submissions.

Does your manuscript avoid these patterns?

The quick diagnostic reads your full manuscript against Lancet Oncology's criteria and flags the specific issues most likely to cause rejection.

Run Free Readiness Scan →

Insider Tips from Lancet Oncology Authors

Speed is genuinely valued and expected

14-day editorial decisions aren't marketing; they're real. If your research is time-sensitive (new drug approval, emerging resistance), this is your venue.

Global health framing opens doors

Even if your study is from a high-income country, discussing relevance to global cancer care aligns with Lancet priorities.

Real-world evidence complements trials

Registry studies, population-based cohorts, and effectiveness research that validate trial findings in practice are increasingly valued.

Lancet Commissions shape priorities

Current Lancet initiatives (cancer and climate change, cancer equity, etc.) influence editorial priorities. Alignment with these themes helps.

Phase 3 negative trials can be published

Well-designed trials showing treatments don't work are valuable. They prevent adoption of ineffective therapies globally.

Quality of life data strengthens submissions

Patient-reported outcomes, functional status, and quality of life measures are increasingly required for cancer trials.

International collaborations are prized

Multi-country studies, especially with meaningful LMIC participation, align with Lancet's global vision.

Editorial commentary can accompany papers

High-impact papers often receive commissioned commentary. This amplifies reach and influence within the oncology community.

The Lancet Oncology Submission Process

Presubmission inquiry (optional)

Response within 1 week

Brief pitch for time-sensitive or unusual studies. Most submissions go directly to full submission.

Full submission

Initial decision ~14 days

Complete manuscript emphasizing clinical impact and global relevance. Clear trial registration and adherence to reporting guidelines required.

Editorial assessment

~1 week

Rapid evaluation of practice impact, global relevance, and methodological rigor. High desk rejection rate.

Peer review

2-3 weeks

Expert oncologists and methodologists. Focus on clinical significance and implementation potential.

Decision and revision

Rapid turnaround expected

Fast decisions with focused revision requests. Multiple rounds possible but typically efficient.

Lancet Oncology by the Numbers

2024 Impact Factor(Clarivate JCR, top oncology journal)	51.1
Submissions per year	~2,500
Acceptance rate	~8%
Time to first decision	14 days median
Desk rejection rate	~75%
Post-review acceptance	~30% of reviewed
Monthly publication	12 issues/year
Global readership	Part of 1M+ Lancet family readers

Before you submit

Lancet Oncology accepts a small fraction of submissions. Make your attempt count.

The pre-submission diagnostic runs a live literature search, scores your manuscript section by section, and gives you a prioritized fix list calibrated to Lancet Oncology. ~30 minutes.

Run Free Readiness Scan See a sample report

Article Types

Article

3,500 words

Full reports of practice-changing cancer research

Fast-Track Article

Shorter; expedited process

Time-sensitive findings requiring urgent publication

Review

4,000 words

In-depth reviews of important oncology topics

Personal View

1,200 words

Opinion pieces on cancer policy and practice

Landmark Lancet Oncology Papers

Papers that defined fields and changed science:

Herceptin in HER2-positive breast cancer - HERA trial (Piccart-Gebhart et al., 2005)
Pembrolizumab in melanoma - KEYNOTE-001 (Robert et al., 2015)
CAR-T therapy in acute lymphoblastic leukemia (Maude et al., 2018)
PARP inhibitor maintenance in ovarian cancer - SOLO1 (Moore et al., 2018)
Durvalumab after chemoradiotherapy in lung cancer - PACIFIC (Antonia et al., 2017)

Preparing a Lancet Oncology Submission?

Get pre-submission feedback from reviewers who've published in Lancet Oncology and know exactly what editors look for.

Run Free Readiness Scan

Need expert depth? Human review from $1,000

NDA-protected

Confidential

Primary Fields

Medical OncologyRadiation OncologySurgical OncologyCancer EpidemiologyCancer PolicyGlobal OncologyPrecision Medicine

Related Journal Guides

All journal guides

All articles

Ready to submit to Lancet Oncology?

A desk rejection costs months. Get expert feedback before you submit, from scientists who know exactly what Lancet Oncology editors look for.

Need field-expert depth? Human review from $1,000